Brickell Biotech Inc (NASDAQ:BBI) Stock Sees Profit Booking At Higher Level
Clinical stage pharmaceutical firm Brickell Biotech Inc (NASDAQ:BBI) saw its stock correct quite sharply on Wednesday as it ended the day with a decline of 6% amidst a selloff. That being said, it is perhaps also important to keep in mind that over the course of the past week the stock is still up by as much as 12%. Trading Data On Wednesday, BBI stock fell 5.73% to $0.24 with…